These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 33772427

  • 1. A tumor-promoting role for soluble TβRIII in glioblastoma.
    Burghardt I, Schroeder JJ, Weiss T, Gramatzki D, Weller M.
    Mol Cell Biochem; 2021 Aug; 476(8):2963-2973. PubMed ID: 33772427
    [Abstract] [Full Text] [Related]

  • 2. Type III TGF-β receptor enhances colon cancer cell migration and anchorage-independent growth.
    Gatza CE, Holtzhausen A, Kirkbride KC, Morton A, Gatza ML, Datto MB, Blobe GC.
    Neoplasia; 2011 Aug; 13(8):758-70. PubMed ID: 21847367
    [Abstract] [Full Text] [Related]

  • 3. The balance of cell surface and soluble type III TGF-β receptor regulates BMP signaling in normal and cancerous mammary epithelial cells.
    Gatza CE, Elderbroom JL, Oh SY, Starr MD, Nixon AB, Blobe GC.
    Neoplasia; 2014 Jun; 16(6):489-500. PubMed ID: 25077702
    [Abstract] [Full Text] [Related]

  • 4. Loss of type III transforming growth factor beta receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression.
    Gordon KJ, Dong M, Chislock EM, Fields TA, Blobe GC.
    Carcinogenesis; 2008 Feb; 29(2):252-62. PubMed ID: 17999987
    [Abstract] [Full Text] [Related]

  • 5. Differential regulation of TGF-β-induced, ALK-5-mediated VEGF release by SMAD2/3 versus SMAD1/5/8 signaling in glioblastoma.
    Seystahl K, Tritschler I, Szabo E, Tabatabai G, Weller M.
    Neuro Oncol; 2015 Feb; 17(2):254-65. PubMed ID: 25165192
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Ectodomain shedding of TβRIII is required for TβRIII-mediated suppression of TGF-β signaling and breast cancer migration and invasion.
    Elderbroom JL, Huang JJ, Gatza CE, Chen J, How T, Starr M, Nixon AB, Blobe GC.
    Mol Biol Cell; 2014 Aug 15; 25(16):2320-32. PubMed ID: 24966170
    [Abstract] [Full Text] [Related]

  • 8. Decreased expression of the type III TGF-β receptor enhances metastasis and invasion in hepatocellullar carcinoma progression.
    Zhang S, Sun WY, Wu JJ, Gu YJ, Wei W.
    Oncol Rep; 2016 Apr 15; 35(4):2373-81. PubMed ID: 26882862
    [Abstract] [Full Text] [Related]

  • 9. USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma.
    Eichhorn PJ, Rodón L, Gonzàlez-Juncà A, Dirac A, Gili M, Martínez-Sáez E, Aura C, Barba I, Peg V, Prat A, Cuartas I, Jimenez J, García-Dorado D, Sahuquillo J, Bernards R, Baselga J, Seoane J.
    Nat Med; 2012 Feb 19; 18(3):429-35. PubMed ID: 22344298
    [Abstract] [Full Text] [Related]

  • 10. Identification of soluble transforming growth factor-beta receptor III (sTbetaIII) in rat milk.
    Zhang M, Zola H, Read L, Penttila I.
    Immunol Cell Biol; 2001 Jun 19; 79(3):291-7. PubMed ID: 11380683
    [Abstract] [Full Text] [Related]

  • 11. Increased type III TGF-β receptor shedding decreases tumorigenesis through induction of epithelial-to-mesenchymal transition.
    Huang JJ, Corona AL, Dunn BP, Cai EM, Prakken JN, Blobe GC.
    Oncogene; 2019 May 19; 38(18):3402-3414. PubMed ID: 30643193
    [Abstract] [Full Text] [Related]

  • 12. Transforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer.
    Jovanović B, Beeler JS, Pickup MW, Chytil A, Gorska AE, Ashby WJ, Lehmann BD, Zijlstra A, Pietenpol JA, Moses HL.
    Breast Cancer Res; 2014 Jul 01; 16(4):R69. PubMed ID: 24985072
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of type III TGF-β receptor aggravates lung fibrotic process.
    Ahn JY, Park S, Yun YS, Song JY.
    Biomed Pharmacother; 2010 Sep 01; 64(7):472-6. PubMed ID: 20359848
    [Abstract] [Full Text] [Related]

  • 14. The type III TGF-beta receptor suppresses breast cancer progression.
    Dong M, How T, Kirkbride KC, Gordon KJ, Lee JD, Hempel N, Kelly P, Moeller BJ, Marks JR, Blobe GC.
    J Clin Invest; 2007 Jan 01; 117(1):206-17. PubMed ID: 17160136
    [Abstract] [Full Text] [Related]

  • 15. Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma.
    Cooper SJ, Zou H, Legrand SN, Marlow LA, von Roemeling CA, Radisky DC, Wu KJ, Hempel N, Margulis V, Tun HW, Blobe GC, Wood CG, Copland JA.
    Oncogene; 2010 May 20; 29(20):2905-15. PubMed ID: 20208565
    [Abstract] [Full Text] [Related]

  • 16. The type III TGF-beta receptor suppresses breast cancer progression through GIPC-mediated inhibition of TGF-beta signaling.
    Lee JD, Hempel N, Lee NY, Blobe GC.
    Carcinogenesis; 2010 Feb 20; 31(2):175-83. PubMed ID: 19955393
    [Abstract] [Full Text] [Related]

  • 17. Type III TGF-β receptor inhibits cell proliferation and migration in salivary glands adenoid cystic carcinoma by suppressing NF-κB signaling.
    Xu D, Li D, Lu Z, Dong X, Wang X.
    Oncol Rep; 2016 Jan 20; 35(1):267-74. PubMed ID: 26531330
    [Abstract] [Full Text] [Related]

  • 18. Oncogenic Ki-ras confers a more aggressive colon cancer phenotype through modification of transforming growth factor-beta receptor III.
    Yan Z, Deng X, Friedman E.
    J Biol Chem; 2001 Jan 12; 276(2):1555-63. PubMed ID: 11029459
    [Abstract] [Full Text] [Related]

  • 19. Bone morphogenetic proteins signal through the transforming growth factor-beta type III receptor.
    Kirkbride KC, Townsend TA, Bruinsma MW, Barnett JV, Blobe GC.
    J Biol Chem; 2008 Mar 21; 283(12):7628-37. PubMed ID: 18184661
    [Abstract] [Full Text] [Related]

  • 20. TβRIII independently binds type I and type II TGF-β receptors to inhibit TGF-β signaling.
    Tazat K, Hector-Greene M, Blobe GC, Henis YI.
    Mol Biol Cell; 2015 Oct 01; 26(19):3535-45. PubMed ID: 26269580
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.